27 results
424B5
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Prospectus supplement for primary offering
5:27pm
or instrumentalities thereof;
certain former U.S. citizens or long-term residents;
tax-exempt entities (including private foundations);
persons liable … capital gain or loss will be long term if the ordinary shares have been held for more than one year and will generally be U.S.-source gain or loss
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
12 Jan 24
Current report (foreign)
7:43am
years of cash flow projections are based on the Company's long-term financial projections, including the launch and commercialization of products
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
21 Dec 23
Current report (foreign)
7:34am
to evaluate the long term effects of respiratory infections on the immune system in many different contexts including long COVID and progression
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
18 Dec 23
Virax Biolabs’ CEO James Foster Issues Letter to Shareholders
7:37am
million individuals in the US and 38 million in Europe. Individuals experiencing Long COVid can experience debilitating symptoms long-term resulting
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
31 Oct 23
Current report (foreign)
4:38pm
of a financial reporting measure:
·Annual bonuses and other short- and long-term cash incentives.
·Stock options.
·Stock appreciation rights.
·Restricted
6-K
EX-99.1
rtcsty0nbz3hj
12 Sep 23
Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar
7:49am
6-K
EX-99.1
lqmmxjly
14 Jun 23
Virax Biolabs' CEO James Foster Issues Letter to Shareholders
8:00am
424B3
ea2tg7nwif eeh80a4
31 Mar 23
Prospectus supplement
4:04pm
424B3
esdjmi9ij7 e5
2 Dec 22
Prospectus supplement
4:17pm
F-1
jpyxfda
18 Nov 22
Registration statement (foreign)
5:39pm
6-K
EX-99.1
0sxdwd19clu
26 Oct 22
Virax Biolabs Group Limited Announces Initiation of its Virax Immune COVID-19 Analytical Performance Study
7:56am
20-F
99mkb5pfv3 4r9
12 Aug 22
Annual report (foreign)
4:20pm
424B4
zmgzyqrkwh
21 Jul 22
Prospectus supplement with pricing info
10:01am
FWP
1957askkz 6iiyu7po
30 Jun 22
Free writing prospectus
9:04pm
FWP
v2muh9k
30 Jun 22
Free writing prospectus
1:29pm
F-1/A
3kr yva48wt55d
24 Jun 22
Registration statement (foreign) (amended)
9:47pm
F-1/A
rdwhv4v2wsuvwceuvazu
24 Jun 22
Registration statement (foreign) (amended)
8:21am
F-1/A
4nkpy1xz
21 Jun 22
Registration statement (foreign) (amended)
6:26am
F-1/A
w3a3j
6 Jun 22
Registration statement (foreign) (amended)
6:13pm